Evoke Pharma Inc (NASDAQ:EVOK) shares shot up 5.1% during mid-day trading on Monday . The stock traded as high as $1.05 and last traded at $1.03, 1,006,480 shares were traded during mid-day trading. An increase of 35% from the average session volume of 745,941 shares. The stock had previously closed at $0.98.

Several research analysts have commented on EVOK shares. HC Wainwright cut shares of Hydrogenics from a “buy” rating to a “neutral” rating in a report on Friday, June 28th. Zacks Investment Research cut shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Finally, ValuEngine upgraded shares of XCel Brands from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th.

The company has a market cap of $21.14 million, a price-to-earnings ratio of -2.24 and a beta of 1.62. The company has a fifty day moving average of $0.80.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, sell-side analysts forecast that Evoke Pharma Inc will post -0.41 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new stake in Evoke Pharma in the first quarter valued at approximately $139,000. BlackRock Inc. lifted its stake in Evoke Pharma by 5.5% in the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after acquiring an additional 4,392 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Evoke Pharma in the first quarter valued at approximately $118,000. Institutional investors and hedge funds own 7.40% of the company’s stock.

About Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Read More: What does an outperform rating mean?

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.